Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: A randomised study

Digestive and Liver Disease

Volumn 46, Issue 3, 2014, Pages 251-256

  Hobolth, Lise ^a,b   Bendtsen, Flemming ^b   Hansen, Erik F ^b   Møller, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Carvedilol; Haemodynamics; Propranolol; Randomised trial

Indexed keywords

CARVEDILOL; PROPRANOLOL; RENIN;

ADULT; ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTERY COMPLIANCE; ARTICLE; BLOOD VOLUME; CAUSE OF DEATH; CIRCULATION TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART OUTPUT; HEART RATE; HEMATEMESIS; HEMODYNAMICS; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LUNG ALVEOLUS OXYGEN TENSION; MALE; MIDDLE AGED; OXYGEN SATURATION; PLASMA RENIN ACTIVITY; PLASMA VOLUME; PORTAL HYPERTENSION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; VENOUS PRESSURE;

CARVEDILOL; HAEMODYNAMICS; PROPRANOLOL; RANDOMISED TRIAL;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ARTERIES; BLOOD PRESSURE; BLOOD VOLUME; CARBAZOLES; CARDIAC OUTPUT; COMPLIANCE; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OXIMETRY; PLASMA VOLUME; PORTAL PRESSURE; PROPANOLAMINES; PROPRANOLOL; RENIN; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84893752050     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.013     Document Type: Article

References (33)

1. Bendtsen F., Krag A., Moller S. Treatment of acute variceal bleeding. Digestive and Liver Disease 2008, 40:328-336.
2. Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. New England Journal of Medicine 2010, 362:823-832.
3. Thalheimer U., Triantos C., Goulis J., et al. Management of varices in cirrhosis. Expert Opinion on Pharmacotherapy 2011, 12:721-735.
4. Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. Journal of Clinical Gastroenterology 2007, 41(Suppl 3):S288-S294.
5. Cardenas A., Gines P. Acute-on-chronic liver failure: the kidneys. Current Opinion in Critical Care 2011, 17:184-189.
6. Liu H., Lee S.S. Acute-on-chronic liver failure: the heart and systemic hemodynamics. Current Opinion in Critical Care 2011, 17:190-194.
7. Moller S., Henriksen J.H. Cirrhotic cardiomyopathy. Journal of Hepatology 2010, 53:179-190.
8. Garcia-Pagan J.C. Portal hypertension: nonselective beta-blockers in patients with refractory ascites. Nature Reviews Gastroenterology & Hepatology 2011, 8:10-11.
9. Tripathi D., Hayes P.C. The role of carvedilol in the management of portal hypertension. European Journal of Gastroenterology and Hepatology 2010, 22:905-911.
10. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010, 51:2214-2218.
11. Forrest E.H., Bouchier I.A., Hayes P.C. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. Journal of Hepatology 1996, 25:909-915.
12. Tripathi D., Therapondos G., Lui H.F., et al. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics 2002, 16:373-380.
13. Lin H.C., Yang Y.Y., Hou M.C., et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. American Journal of Gastroenterology 2004, 99:1953-1958.
14. Banares R., Moitinho E., Matilla A., et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002, 36:1367-1373.
15. Reiberger T., Ulbrich G., Ferlitsch A., et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2012, 10.1136/gutjnl-2012-304038.
16. Banares R., Moitinho E., Piqueras B., et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999, 30:79-83.
17. Serste T., Melot C., Francoz C., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010, 52:1017-1022.
18. Serste T., Francoz C., Durand F., et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. Journal of Hepatology 2011, 55:794-799.
19. Hobolth L., Moller S., Gronbaek H., et al. Carvedilol or propranolol in portal hypertension. A randomized comparison. Scandinavian Journal of Gastroenterology 2012, 47:467-474.
20. Moller S., Bendtsen F., Henriksen J.H. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995, 109:1917-1925.
21. Henriksen J.H., Winkler K. Hepatic blood flow determination. A comparison of 99mTc-diethyl-IDA and indocyanine green as hepatic blood flow indicators in man. Journal of Hepatology 1987, 4:66-70.
22. Moller S., Hillingso J., Christensen E., et al. Arterial hypoxaemia in cirrhosis: fact or fiction. Gut 1998, 42:868-874.
23. Moller S., Henriksen J.H., Bendtsen F. Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. American Journal of Physiology - Gastrointestinal and Liver Physiology 2003, 284:G970-G979.
24. Henriksen J.H., Fuglsang S., Bendtsen F., et al. Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. American Journal of Physiology - Gastrointestinal and Liver Physiology 2001, 280:G584-G594.
25. Hansen S., Moller S., Bendtsen F., et al. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. Journal of Hepatology 2007, 47:373-380.
26. Goetze J.P., Dahlstrom U., Rehfeld J.F., et al. Impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement. Clinical Chemistry 2008, 54:1780-1787.
27. Henriksen J.H., Gotze J.P., Fuglsang S., et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003, 52:1511-1517.
28. Hunter I., Alehagen U., Dahlstrom U., et al. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. Clinical Chemistry 2011, 57:1327-1330.
29. Moller S., Bendtsen F., Henriksen J.H. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scandinavian Journal of Gastroenterology 2006, 41:451-458.
30. Dupont A.G. Effects of carvedilol on renal function. European Journal of Clinical Pharmacology 1990, 38(Suppl 2):S96-S100.
31. Bernardi M., Calandra S., Colantoni A., et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and i of the disease and possible pathogenetic factors. Hepatology 1998, 27:28-34.
32. c) in patients with cirrhosis. Journal of Hepatology 2004, 40:239-246.
33. Lee R.F., Glenn T.K., Lee S.S. Cardiac dysfunction in cirrhosis. Best Practice and Research. Clinical Gastroenterology 2007, 21:125-140.